<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848327</url>
  </required_header>
  <id_info>
    <org_study_id>20120415</org_study_id>
    <secondary_id>5559072</secondary_id>
    <nct_id>NCT01848327</nct_id>
  </id_info>
  <brief_title>Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis</brief_title>
  <official_title>A Randomized Double-Blind Placebo-Controlled Study of Caprylic Triglyceride for Cognitive Impairment in Subjects With Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cerecin</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background/Rationale: Cognitive problems are a common symptom in individuals with Multiple&#xD;
      Sclerosis (MS). Treatment options are limited, and there is a pressing need for new&#xD;
      interventions to treat MS-related cognitive impairment. Glucose (a type of sugar) is used to&#xD;
      fuel the cells of the healthy brain. For people with neurological conditions such as MS,&#xD;
      glucose is not converted into energy as efficiently as it would be in a healthy brain, which&#xD;
      can lead to a decrease in cognitive function. Caprylic Triglyceride may work to bypass this&#xD;
      problem by providing an alternative energy source that is metabolized in the liver and used&#xD;
      by the brain.&#xD;
&#xD;
      Objective: To evaluate the therapeutic effects of 90 days of caprylic triglyceride on&#xD;
      cognitive impairment in multiple sclerosis.&#xD;
&#xD;
      Design: Randomized, double blinded, placebo controlled trial of 158 subjects.&#xD;
&#xD;
      Outcome: Change in Total Learning (Trials 1-5) on the California Verbal Learning Test-2nd&#xD;
      Edition-(CVLT-II) AND Change in Symbol Digit Modalities Test (SDMT) (at day 90&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with all types of MS (Relapsing Remitting, Secondary Progressive, or Primary&#xD;
      Progressive) are eligible to participate. Participants will undergo detailed cognitive&#xD;
      assessment before initiating treatment and again after 90 days of treatment, to determine&#xD;
      whether Caprylic Triglyceride demonstrates a benefit over placebo.&#xD;
&#xD;
      Dosage: 40 gram packet orally once a day Duration of Treatment: 90 days&#xD;
&#xD;
      Analyses: Interim analyses will be conducted after 72 subjects have completed the trial and&#xD;
      objective STOP criteria for efficacy and futility have been defined in the protocol. Final&#xD;
      analyses will be an intent-to-treat (ITT) analysis to evaluate each of the primary aims.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Learning (Trials 1-5) on the California Verbal Learning Test-2nd Edition (CVLT-II) (range from 0 to 80)</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>measure of verbal learning and memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Symbol Digit Modalities Test (SDMT) (range from 0-110)</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>measure of processing speed and attention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants reporting adverse events</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>The number of participants experiencing adverse events in the active treatment and placebo group will be examined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EDSS</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>measure of disease severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beck Depression Inventory -2nd edition (BDI-II)</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Self-report depression scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multiple Sclerosis Quality of Life Inventory (MSQOL-54)</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Quality of life inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Self-report Fatigue scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Relapsing Remitting MS</condition>
  <condition>Secondary Progressive MS</condition>
  <condition>Primary Progressive MS</condition>
  <arm_group>
    <arm_group_label>Caprylic Triglyceride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caprylic Triglyceride (40 gram packet orally once a day for 90 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (40 gram packet orally once a day for 90 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Caprylic Triglyceride</intervention_name>
    <description>Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.</description>
    <arm_group_label>Caprylic Triglyceride</arm_group_label>
    <other_name>Axona</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (40 gram packet orally once a day for 90 days)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Institutional Review Board (IRB)-approved Informed Consent Form signed by patient&#xD;
&#xD;
          2. A diagnosis of MS as defined by the Revised McDonald criteria.&#xD;
&#xD;
          3. All subtypes of MS, relapsing and progressive, are eligible.&#xD;
&#xD;
          4. Males and females age 18 to 59 years old.&#xD;
&#xD;
          5. Complaints of difficulties with memory or other aspects of cognition.&#xD;
&#xD;
          6. Mini-Mental Status Exam (MMSE) score &gt;=24 for determination of ability to provide&#xD;
             informed consent.&#xD;
&#xD;
          7. 8th grade English reading proficiency as determined by Wide Range Achievement Test-4th&#xD;
             edition-reading .&#xD;
&#xD;
          8. Females of childbearing potential must have a negative pregnancy test prior to entry&#xD;
             into treatment phase and must simultaneously use two forms of effective contraception&#xD;
             during the treatment and for one month or one menstrual cycle after discontinuation of&#xD;
             the study medication.&#xD;
&#xD;
          9. All concomitant medication doses must be stable for at least 30 days prior to&#xD;
             randomization and remain stable for the study duration.&#xD;
&#xD;
         10. An Expanded Disability Status Scale (EDSS) score of at least a 2.0 with a Functional&#xD;
             System Score of at least a 2 in the Cerebral section due to decreased mentation.&#xD;
&#xD;
         11. Stable neurologic function with no multiple sclerosis relapses for at least 30 days&#xD;
             prior to study entry.&#xD;
&#xD;
         12. No clinically significant abnormal findings on the physical examination, medical&#xD;
             history, or clinical laboratory results during Screen.&#xD;
&#xD;
         13. Documented memory deficit as defined by a score at least 0.5 standard deviations (SD)&#xD;
             below age- and gender-based normative values on the Total Learning Score of the&#xD;
             CVLT-II OR a documented processing speed deficit as defined by a score of at least 1.0&#xD;
             SD below normative values on the SDMT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition that would render the patient or the caregiver unsuitable for the study,&#xD;
             or place them at substantial risk of adverse outcome.&#xD;
&#xD;
          2. Unwillingness/inability of the patient to fulfill the study requirements.&#xD;
&#xD;
          3. Evidence of major depression or a score on the BDI-II &gt; or = 30 OR a score &lt; 30 on&#xD;
             BDI-II but with endorsed suicidal ideation.&#xD;
&#xD;
          4. Hypothyroidism&#xD;
&#xD;
          5. B12 deficiency&#xD;
&#xD;
          6. Diabetes (Type 1 or 2).&#xD;
&#xD;
          7. Positive rapid plasma reagin.&#xD;
&#xD;
          8. Fasting triglyceride level&gt;2 times upper limit of normal value w/in 3 months of Study&#xD;
             Visit 1.&#xD;
&#xD;
          9. History of malignancy of any organ system (other than localized squamous and basal&#xD;
             cell carcinoma of the skin), treated or untreated, within the past 2 years.&#xD;
&#xD;
         10. Clinically significant renal disease or insufficiency.&#xD;
&#xD;
         11. Clinically significant hepatic disease or insufficiency.&#xD;
&#xD;
         12. Ethanol consumption greater than an equivalent of 2 oz/20 g/2 units of spirits per day&#xD;
             OR 14 oz/140 g/14 units of spirits per week. One oz/10 g/1 unit of spirits = 6 oz/15&#xD;
             g/1 unit of wine = 12 oz/12 g/1 unit of beer.&#xD;
&#xD;
         13. History of current alcohol or substance abuse.&#xD;
&#xD;
         14. Known HIV infection.&#xD;
&#xD;
         15. History of head injury with loss of consciousness &gt; 30 minutes.&#xD;
&#xD;
         16. History of inflammatory bowel syndrome.&#xD;
&#xD;
         17. History of severe irritable bowel disease.&#xD;
&#xD;
         18. History of severe gastroesophageal reflux disease.&#xD;
&#xD;
         19. History of diverticular disease.&#xD;
&#xD;
         20. Use of any investigational compound within 30 days prior to screening.&#xD;
&#xD;
         21. Prior or current use of medium chain triglycerides for medical purposes.&#xD;
&#xD;
         22. Known allergies to dairy products or soy.&#xD;
&#xD;
         23. Use of anticholinergic medication within 30 days prior to Study Visit 1.&#xD;
&#xD;
         24. Use of acetylcholinesterase inhibitors within 30 days prior to Study Visit 1.&#xD;
&#xD;
         25. Use of memantine within 30 days prior to Study Visit 1.&#xD;
&#xD;
         26. Use of stimulants within 30 days prior to Study Visit 1&#xD;
&#xD;
         27. Use of modafinil, amantadine, and dalfampridine within 30 days prior to Study Visit 1,&#xD;
             unless the dose has been stable for 90 days prior to Study Visit 1&#xD;
&#xD;
         28. Use of orlistat within 30 days prior to Study Visit 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leticia Tornes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Leticia Tornes</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Cognition</keyword>
  <keyword>Neuropsychology</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Via Publications</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

